on January 26, 2004
Published online before print January 26, 2004, doi: 10.1161/01.CIR.0000114526.50618.24
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© American Heart Association, Inc.
Basic Science Reports |
C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice
From the Division of Diabetes, Endocrinology and Metabolism, Departments of Medicine and Molecular & Cellular Biology, (A.P., K.W.S.K., L.L., V.Y., L.C.) Baylor College of Medicine, Houston, Tex, and Division of Clinical Immunology and Rheumatology, Department of Medicine, (M.A.M., A.J.S.) University of Alabama at Birmingham, Birmingham, Ala.
Correspondence to Dr Lawrence Chan, Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Baylor College of Medicine N510.20, One Baylor Plaza, Houston, TX 77030. E-mail lchan{at}bcm.tmc.edu
Received November 6, 2003; revision received December 5, 2003; accepted December 10, 2003.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Plasma C-reactive protein (CRP) concentration is a strong predictor of atherosclerosis. However, to date, there is no in vivo evidence that CRP is proatherogenic.
Methods and Results— We studied the effect of human CRP transgene (tg) expression, under basal and turpentine-stimulated conditions, on atherosclerosis in apolipoprotein (apo) E-/- mice. Aortic atherosclerotic lesions in 29-week-old male mice were 48% larger (P<0.02) in turpentine-treated mice and 34% larger (P<0.05) in untreated CRPtg+/0/apoE-/- mice. Turpentine treatment per se did not affect the extent of atherosclerosis in CRP transgenic or nontransgenic apoE-/- mice. Transgenic mice exhibited lower plasma complement C3 but increased deposition of CRP and C3 in the lesions, which suggests that CRP stimulated activation of complement within the lesion. There was more intense and widespread vascular cell adhesion molecule-1 and collagen staining in the lesions of CRPtg+/0/apoE-/- mice than in CRPtg0/0/apoE-/- littermates. Lesions of CRPtg+/0/apoE-/- mice contained increased angiotensin type 1 receptor (AT1-R) transcripts and displayed increased AT1-R immunostaining compared with those of CRPtg0/0/apoE-/- mice. There was no difference in blood pressure in the 2 types of mice, which indicates that the proatherogenic effect of CRP-associated AT1-R overexpression is local and not mediated by its hypertensive properties.
Conclusions— Human CRP transgene expression causes accelerated aortic atherosclerosis in apoE-/- mice. CRP was detected in the lesion, which was associated with increased C3 deposition and increased AT1-R, vascular cell adhesion molecule-1, and collagen expression. These data document a proatherogenic role for CRP in vivo.
Key Words: C-reactive protein • angiotensin • atherosclerosis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Atherosclerosis is an important underlying pathology of cardiovascular disease (CVD), the leading cause of morbidity and mortality in developed countries.1 Clinical markers for atherosclerosis are a useful tool for identifying individuals at high risk for CVD development. C-reactive protein (CRP) has been recommended as the marker of choice to monitor cardiovascular risk, being a stronger predictor of atherosclerosis than even plasma LDL concentration.2,3 Inflammation is a prominent feature of atherosclerosis,1,4 and it is postulated that as an acute-phase protein, elevation of plasma CRP may signal the underlying atherosclerotic process. Although numerous epidemiological studies have shown that plasma CRP level is an excellent independent predictor of CVD in both men and women3,5 and an excellent marker of the rate of progression of atherosclerosis,6,7 to date there is no proof that CRP is an active participant in the atherogenic process in vivo. Because atherosclerosis is an inflammatory condition, it is possible that plasma CRP levels rise as a result of the atherosclerotic process. However, the lack of association between CRP levels and extent of atherosclerosis quantified by imaging is evidence against CRP elevation being purely a consequence of atherosclerosis development.2
There is substantial circumstantial evidence that CRP may be directly involved in atherogenesis, ie, that CRP is a risk factor. CRP binds to a large number of autologous and extrinsic ligands, including native and modified plasma lipoproteins, phospholipids, and apoptotic cells, which are present in the atherosclerotic lesions.8 When bound to ligands, CRP activates the classic pathway of complement, a major player in the immune and inflammatory response, and reacts with Fc
receptors on phagocytic cells.8–10 Both CRP and complement are known to colocalize in human atherosclerotic lesions, which suggests that CRP, by activating the complement, may be an active participant in atherosclerosis development.11
In vitro experiments showed that CRP modulates the activity and expression of multiple factors implicated in atherogenesis. It downregulates endothelial nitric oxide synthase (eNOS)12,13 and stimulates the production of endothelin-1 (ET-1) in endothelial cells in vitro.14 CRP may also facilitate leukocyte adhesion and internalization into the arterial wall by stimulating the expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1, E-selectin, and monocyte chemoattractant protein-1.15,16 Moreover, CRP itself was found to be chemotactic for monocytes17; it also binds to oxidized LDL18 and facilitates the uptake of LDL by macrophages.10,19 CRP increases smooth muscle cell (SMC) migration and neointimal formation after carotid angioplasty in rats.20 It may also activate nuclear factor-
B and activator protein-1 (AP-1) and upregulate angiotensin type 1 receptors (AT1-R) in human vascular SMCs, which could mediate many of the proinflammatory effects of angiotensin (Ang) II.20,21
The numerous reported potential proatherogenic properties of CRP notwithstanding, there is no direct evidence that CRP plays an active role in atherosclerosis in vivo. Therefore, to date, it is not known if CRP is a risk marker or an actual risk factor for atherosclerosis.2 In fact, there are properties associated with CRP that can be interpreted as having a vasculoprotective or an antiatherogenic function, eg, CRP was shown to relax human vessels in vitro22 and to inhibit basal and vascular endothelial growth factor–stimulated angiogenesis,12 which would in turn inhibit plaque neovascularization,23 macrophage accumulation, and lesion progression.23,24 To determine whether CRP is solely a risk marker for atherosclerosis or is also an active player in vivo, we have undertaken this study to examine the effect of transgenic expression of human CRP on atherosclerosis development in apolipoprotein (apo) E-/- mice.25 The data show that expression of human CRP in mice accelerates aortic atherosclerotic lesion progression, thus providing the first evidence that CRP is indeed a risk factor and an active player in atherogenesis in vivo.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mice
The protocol for this study was approved by the Institutional Animal Care and Use Committee from Baylor College of Medicine. CRP transgenic mice, congenic to the C57BL/6J strain, were derived from mice originally described by Ciliberto et al.26 Homozygous CRP transgenic mice were crossed twice with apoE-/- (B6.129P2-Apoetm1Unc, Jackson Laboratories, Bar Harbor, Me) to generate hemizygous transgenic CRP (CRPtg+/0) mice on an apoE-/- background. Mice had free access to water and standard laboratory chow.
CRPtg+/0/apoE-/- mice were crossed with CRPtg0/0/apoE-/- mice to generate the mice used for the present study. Mice in 2 paired groups were killed at 15 weeks of age (short-term study), when the atherosclerotic lesions would consist mainly of fatty streaks.27 Mice in another 2 paired groups were killed at 29 weeks of age (long-term study), when apoE-/- mice would be expected to possess advanced atherosclerotic lesions.27 In both experiments, each group of mice was further divided into 2 subgroups. Half of these mice were treated with turpentine injections to induce inflammation, and the other half received no treatment. The number of mice, distribution of CRP genotypes, and treatments received among the different groups of apoE-/- mice are shown in Table 1.
|
Induction of Inflammation
We induced inflammation in some of the mice using turpentine injections as described previously.28 Briefly, once every 14 days, we anesthetized the mice by intraperitoneal administration of Avertin (2,2,2-tribromoethanol, 0.4 mL of a 25 mg/mL solution [Aldrich]) and injected subcutaneously 0.1 mL of a 1:1 mixture of turpentine (Fisher Scientific) and peanut oil (Acros Organics).
Blood and Plasma Parameters and Blood Pressure Measurements
Plasma cholesterol and triglyceride levels were measured at 8 weeks (baseline) and at 15 and 29 weeks by microtiter assays with kits from WAKO Chemicals USA, Inc. We fractionated plasma into lipoprotein fractions by fast-performance liquid chromatography gel filtration using Superose 6B columns (Pharmacia LKB Biotechnology).29 Plasma human CRP concentrations were measured by an ELISA kit (Anogen). For quantifying the relative concentration of complement C3, we collected 0.25 µL of plasma from 5 pairs of CRPtg0/0 and CRPtg+/0 littermates and fractionated them on a 15% polyacrylamide gel, which was subsequently used for Western blot analysis29 with goat anti-mouse C3 antibody (ICN Biochemicals).
We measured the systolic and diastolic blood pressures (BP) and resting heart rate using an automated tail-cuff system (BP-2000, Visitech Systems).30 Briefly, the mice were submitted to 3 training sessions in which the measurements were made but not recorded. We then put them through 3 sessions of measurements that were recorded, each including 2 sets of 10 measurements, during 3 consecutive days.
Quantitative Morphometry of Atherosclerotic Lesion Involvement
In 15- and 29-week-old mice, the aortic arch area of apoE-/- mice was the principal part of the aorta that exhibited atherosclerotic lesion formation, which we measured by morphometry of cross sections of the aortic sinus area by a computer-assisted technique, as described previously.31,32 Lesions were essentially absent outside the arch for the 15-week-old group; for 29-week-old animals that had small, demonstrable lesions distal to the aortic arch, we additionally measured the extent of lesion involvement of the rest of the descending aorta by an en face technique using computer-assisted quantitative morphometry.33 We used a digitizing morphometry image-analysis system (AxioVision, Carl Zeiss Vision, GmbH and SigmaScan Pro 5, SPSS Inc) to analyze lesion areas and specifically stained regions.
Immunohistochemistry and Special Stains
We performed immunohistochemistry using primary antibodies specific for CRP (Sigma), Mac-3 (Santa Cruz Biotechnology), 
-actin (Spring Bioscience), VCAM-1 (Santa Cruz Biotechnology), complement C3 (ICN Pharmaceuticals), and AT1-R (Santa Cruz Biotechnology). Briefly, slides holding 5-µm cross sections were immersed in cold acetone, rehydrated in PBS (pH 7.4) and blocked with 3% H2O2 and 3% normal serum from the same animal species in which the secondary antibody was raised. We incubated tissue sections sequentially with primary antibodies and appropriate biotinylated secondary antibodies. Avidin-biotin horseradish peroxidase (Vectastain ABC reagent, Vector Laboratories) and NovaRED substrate kits for peroxidase (Vector Laboratories) were used to visualize the primary antibody. To increase the sensitivity of the immunostain for AT1-R, we used the Dako Envision+ System, Peroxidase (AEC). We used hematoxylin as counterstain and Masson’s trichrome stain to visualize collagen deposits according to standard protocols. For quantification by image analysis, we set a threshold to automatically compute the areas positive for each antibody or histochemical stain and then computed the ratio of positively stained area to the total lesion area studied.
Analysis of mRNA Expression by Real-Time Reverse Transcription–Polymerase Chain Reaction
We isolated RNA from whole aortas of 29-week-old male mice using the Absolutely RNA RT-PCR Miniprep Kit (Stratagene) and performed real-time quantitative reverse transcription–polymerase chain reaction (RT-PCR) with the LightCycler RNA Master SYBR Green I kit (Roche Diagnostics) according to the manufacturer’s instructions. The RT-PCR mixture contained 50 ng of RNA and the following primers: for CRP, 5' primer, 5'-AGC CTC TCT CAT GCT TTT GG-3'; 3' primer, 5'-TGT CTC TTG GTG GCA TAC GA-3'. For AT1-R, 5' primer, 5'-CTG CTC ACG TGT CTC AGC AT-3'; 3' primer, 5'-CGT AAT GAA AAG CGC AAA CA-3'. For eNOS, 5' primer, 5'-GAC CCT CAC CGC TAC AAC AT-3'; 3' primer, 5'-GCT CAT TTT CCA GGT GCT TC-3'. Mouse transferrin was used for RNA template normalization: 5' primer, 5'-GGT GTG CAC TGA GTC ACC TG-3'; 3' primer, 5'-CTC TGC CAT GAC AGG CAC TA-3'. Amplification and detection of specific products were performed with the Opticon System (MJ Research).34
Statistical Analysis
Data were analyzed with SPSS 11.0 for Windows. Most of the outcome parameters used in this study did not follow a normal distribution as judged by Shapiro-Wilk tests, so statistical analyses were performed with Mann-Whitney U tests. Differences were considered significant when P<0.05. In all tables and figures, the results are expressed as mean±SD.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Body Weights, Plasma Lipids, and Hematological Parameters
ApoE-/- mice with and without the CRP transgene had similar body weights and displayed no difference in activity or behavior. Their body weight curves were the same whether CRP was present or not. Body weight was slightly lower (<10% difference) in mice treated with turpentine, but the reduction was the same for turpentine-treated wild-type (CRPtg0/0) and CRPtg+/0 mice (Table 2). Likewise, there was slight variation in plasma cholesterol level, but importantly, there was no difference in plasma cholesterol concentration between CRPtg+/0 and CRPtg0/0 mice in any of the paired groups. Minor but inconsistent differences in plasma triglyceride concentrations were noted. We note that all paired groups were littermates, which probably accounts for the very similar within-treatment lipid profiles (Table 2). We further fractionated the plasma lipoproteins by fast-performance liquid chromatography and found no appreciable difference in the lipoprotein profile between treatment groups (data not shown).
|
Turpentine injections produced a decrease in white blood cell count during the first 24 hours after treatment, which we attribute to migration of the leukocytes to the site of inflammation, followed by a subsequent increase until day 4, when the values returned to the baseline level (data not shown). We observed no effect of the treatment on the number of red blood cells and hematocrit level or on the total platelet count. There was no significant difference between apoE-/- mice, with or without the CRP transgene, in these hematological parameters (data not shown).
CRP Levels in Transgenic Mice
Human CRP was detected in the plasma of CRPtg+/0/apoE-/- but not CRPtg0/0/apoE-/- mice. Consistent with previous observations,35 basal CRP concentration was higher in male than in female CRP transgenic mice (Table 2). On turpentine treatment, the plasma human CRP level of male mice increased from 
100 mg/L to >500 mg/L and gradually decreased toward baseline values by day 4. In females, plasma CRP level increased from 1 to 70 mg/L, again returning toward baseline by day 4 (Figure 1A). Persistently mildly elevated CRP levels were noted in the turpentine-treated female mice throughout the short-term and long-term studies (Table 2).
|
Quantitative Morphometry of Aortic Atherosclerosis Involvement
We had 2 data collection time points, 15 weeks and 29 weeks. A comprehensive analysis of multiple subgroups of animals (8 groups of animals for each time point, or 16 groups for the 2 time points; Table 1) allowed us to discern the effect of gender, stage of maturity of the atherosclerotic lesions, presence and absence of CRP, and presence and absence of overt inflammation and the acute-phase response that may modulate atherosclerosis development. Atherosclerotic lesion involvement in apoE-/- mice was confined mainly to the aortic arch throughout the entire experiment, irrespective of the presence or absence of CRP expression. Morphometric analysis of en face lesions distal to the aortic arch at the 29-week time point revealed very minimal lesion involvement and no significant differences between treatment-matched groups. At the 15-week time point, the degree of aortic arch involvement by cross-section analysis was also relatively mild, and there was no consistent difference between mice with and without CRP (Table 3). However, in 29-week-old mice, the total lesion area was significantly greater in female apoE-/- mice than in treatment-matched male apoE-/- mice, whether or not they carried the CRP transgene. Importantly, at this time point, we also found significantly larger lesion size by cross-sectional analysis of the aortic sinus area in male apoE-/- mice expressing CRP than in age- and treatment-matched males that did not express the protein. The difference in lesion size was large (48% larger in CRPtg+/0 than in CRPtg0/0 mice) and highly significant (P<0.02) when we compared male mice that were treated with turpentine; the difference was not as large, but still substantial (34%) and significant (P<0.05), when we compared male CRPtg+/0/apoE-/- and CRPtg0/0/apoE-/- mice that had not received turpentine (Table 3; Figures 1B and 1C). In female apoE-/- mice with and without the CRP transgene, we observed a similar trend in both turpentine-treated (12% larger in CRPtg+/0) and untreated mice (16% larger in CRPtg+/0), but in neither instance did the difference reach statistical significance (Table 3; Figure 1C). Interestingly, proinflammatory (turpentine) treatment did not significantly affect the size of atherosclerotic lesions in either male or female CRPtg+/0/apoE-/- or CRPtg0/0/apoE-/- mice.
|
CRP and Complement C3 Deposition in Atherosclerotic Lesions
By immunohistochemical analysis, we detected immunoreactive CRP in the lesions of CRPtg+/0/apoE-/- mice and not in those of CRPtg0/0/apoE-/- mice (Figure 2; compare panels A [male] and B [female] CRPtg0/0 versus panels C [male] and D [female] CRPtg+/0 mice). Furthermore, in CRPtg+/0 mice, there was much more intense (compare Figure 2C versus 2D) and widespread (43.74±7.7% in males versus 13.44±7.1% in females, Figure 2E) CRP immunostaining in lesions from male animals compared with those from female animals, which likely reflects the much higher plasma CRP concentration in male versus female CRP transgenic mice (Table 2).
|
Human atherosclerotic lesions have been found to harbor CRP,11 as well as CRP mRNA.36 The possible expression of CRP mRNA in arterial tissue of CRP transgenic mice had not been examined previously. We analyzed for the presence of CRP mRNA by RT-PCR and found that unlike humans, CRP mRNA was detected only in the liver and not the aorta of CRP transgenic mice (Figure 2F). Therefore, the CRP deposited in the atherosclerotic lesion of these animals was most likely derived from the circulation.
Human CRP has been reported to bind to many different autologous and extrinsic ligands.8 When it is bound to macromolecular ligands, CRP activates the classic complement pathway, thereby engaging C3. We determined the relative concentration of plasma C3 by Western blotting and found it to be significantly (44%) lower in CRPtg+/0/apoE-/- than in CRPtg0/0/apoE-/- mice (Figures 3A and 3B). C3 has been reported to be present in human atherosclerotic lesions.37,38 In agreement with the studies in humans and similar studies in mice,39 we found the presence of C3 in the lesion of both CRPtg+/0/apoE-/- and CRPtg0/0/apoE-/- mice (Figures 3C and 3D), which indicates that complement activation or deposition could have occurred in the lesion in both types of animals. The amount of positive immunoreactive C3 staining in the lesion was significantly higher in CRPtg+/0 than in CRPtg0/0 mice lesions (56.3±14.5% in CRPtg+/0 versus 39.1±11.0% in CRPtg0/0, Figure 3E).
|
Phenotypic Analysis of Atherosclerotic Lesions
Phenotypic analysis revealed no obvious difference in terms of atherosclerotic lesion maturity between the 2 groups of mice at 29 weeks; most of the lesions presented with evident fibrous caps and, in some cases, necrotic cores. The areas that stained positive for macrophages were similar in CRPtg+/0 and CRPtg0/0 mice (52.29±11.28% for CRPtg+/0 and 47.12±16.92% for CRPtg0/0). However, we detected a significant increase in the amount of collagen deposited in the lesions in CRPtg+/0/apoE-/- mice compared with CRPtg0/0/apoE-/- mice (48.6±9.75% versus 38.13±9.25%; Figures 4A, 4B, and 4C). Similarly, the amount of immunoreactive VCAM-1 was also increased in the lesion of the CRPtg+/0 animals (29.7±10.5% versus 18.1±9.6%; Figures 4D, 4E, and 4F).
|
Expression of eNOS and AT1-R in CRP Transgenic Mice
CRP has been reported to decrease eNOS expression in cultured human endothelial cells12,13 and to increase AT1-R in cultured human vascular SMC and in vivo in a rat model of carotid angioplasty.20 We quantified the amount of eNOS and AT1-R mRNA by RT-PCR of total RNA extracted from the aorta of CRPtg+/0/apoE-/- and CRPtg0/0/apoE-/- mice. CRP transgene expression did not affect the expression of eNOS [
C(T) relative to transferrin mRNA 0.21±0.13 in CRPtg+/0 versus 0.22±0.15 in CRPtg0/0], but, in turn, it was associated with a 6-fold increase in AT1-R mRNA expression [C(T) relative to transferrin mRNA 0.84±0.37 in CRPtg+/0 versus 0.13±0.09 in CRPtg0/0; Figure 5A]. We observed the presence of immunoreactive AT1-R in lesions from both groups of mice; however, consistent with the increased amounts of AT1-R transcript level, we detected much more intense immunostaining for the protein in CRPtg+/0 than in CRP0/0 mice (Figures 5B and 5C).
|
The upregulated AT1-R protein expression in CRPtg+/0/apoE-/- mice could explain some of the differences in atherosclerotic lesions in CRPtg+/0 versus CRPtg0/0 mice, because AT1-R is a proinflammatory molecule.40,41 To examine whether AT1-R could have led to accelerated atherosclerosis by elevating the BP of CRPtg+/0 mice, we measured the systolic and diastolic BP and the resting heart rate of mice with and without the CRP transgene. We found no significant difference in systolic BP (99.21± 7.91 mm Hg in CRPtg+/0 versus 94.42±7.91 mm Hg in CRPtg0/0; Figure 5D) or diastolic BP (67.63±8.83 mm Hg in CRPtg+/0 versus 64.58±10.95 mm Hg in CRPtg0/0; Figure 5E) or in the resting heart rate (546±20 bpm in CRPtg+/0 versus 547±35 bpm in CRPtg0/0; Figure 5F) in these 2 types of animals. Therefore, the proatherogenic effect of CRP-stimulated AT1-R overexpression appears not to be mediated by a change in BP.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Despite the fact that plasma CRP level has been recommended as a risk marker of choice in predicting atherosclerosis development,2 and numerous reports based on in vitro experiments have strongly suggested a proatherogenic role for CRP, until the present study, there was no evidence to support an active proatherogenic action of CRP in vivo. In this investigation, we show that in male apoE-/- mice, transgenic expression of human CRP accelerates aortic atherosclerosis development. We observed a very substantial and significant effect, ie, a 34% to 48% increase in atherosclerotic lesion area in male mice that express human CRP compared with those that do not (Figures 1B and C; Table 3). A similar but not significant trend was observed in female mice. Interestingly, the proatherogenic effect of CRP was evident in male mice with well-established lesions at 29 weeks but not at 15 weeks, when lesions were mainly composed of fatty streaks, which suggests that CRP affects progression rather than initiation of atherosclerosis. We also saw little difference in lesion size when turpentine injections were used to periodically boost the circulating CRP; hence, the amount of CRP present in male mice under basal conditions appears to be enough to exhibit the proatherogenic effect.
As reviewed in the introduction, on the basis of in vitro experiments, a host of proatherogenic actions of CRP have been reported.10,12,14–21 Among the phenotypic consequences associated with CRP expression that we examined, there are some that warrant additional comment. We detected the presence of CRP in atheromatous lesions (Figure 2), which suggests that part or all of the proatherogenic action of CRP could have been mediated via its local action in the vascular wall where the protein is deposited. Contrary to a report in human lesions,36 we did not detect CRP mRNA expression in the aorta of mice by RT-PCR. Interestingly, we detected increased amounts of C3 deposition in the lesions of CRP transgenic mice, associated with a significantly lower circulating C3 level in these mice (Figure 3). This combination of in vivo findings is consistent with the notion that activation or deposition of complement might play a role in atherogenesis modulated by the presence of CRP.
Another phenotypic feature of atherosclerotic lesions in CRP transgenic mice that may be of pathogenic significance is the increased expression of the AT1-R, both at the mRNA (Figure 5A) and at the protein (immunostaining) level (Figures 5B and 5C). The very impressive (>600%) increase in AT1-R mRNA and the stronger AT1-R immunostaining is consistent with a previous report documenting that CRP upregulates AT1-R in vascular SMCs.20 AT1-R is a major receptor for Ang II that mediates many of the proinflammatory effect of this bioactive molecule. In apoE-/- mice, Ang II infusion was shown to promote atherosclerotic lesions and aneurysm formation in 1 study42 and to accelerate atherosclerosis development by induced hypertension in another.43 In the present study, we found that CRP expression has no significant effect on the blood pressure of apoE-/- mice (Figure 5), which indicates that hypertension is not a factor in the accelerated atherosclerosis of these animals. Therefore, in agreement with previous reports,42,43 Ang II has proatherogenic effects above and beyond its action on BP. Previously reported Ang II effects include reactive oxygen species production, vascular SMC migration, proliferation, extracellular matrix production, and vascular remodeling.44–47 Ang II also induces monocyte chemoattractant protein-1 and VCAM-1 expression.48–50 The much higher AT1-R expression in the presence of the CRP transgene might explain the increased amounts of VCAM-1 (Figures 4D, 4E, and 4F) and collagen deposition (Figures 4A, 4B, and 4C) in the CRPtg+/0 lesions; Ang II has been reported previously to be associated with increased expression of both VCAM-149,50 and collagen in animal models.47
In conclusion, we have shown that CRP expression causes accelerated atherosclerosis progression in apoE-/- mice. A single recent report showed that occlusive thrombosis was more pronounced in CRP transgenic mice than in wild-type mice.51 The present study is the first to confirm a role of CRP in atherosclerosis in vivo, supporting and extending previous observations of potentially proatherogenic actions of CRP in vitro. We conclude that CRP is not merely a risk marker for but also an active participant of atherogenesis in vivo.
|
Acknowledgments |
|---|
This study was supported by National Institutes of Health grant HL-51586 (to Dr Chan) and American Heart Association, Texas Affiliate, grant 0325111Y (to Dr Paul). Dr Chan was supported in part by the Betty Rutherford Chair from the St Luke’s Episcopal Hospital and Baylor College of Medicine. We thank Leslie Wu and members of the Chan research team for assistance with various aspects of the study.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–874.[CrossRef][Medline] [Order article via Infotrieve]
2. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499–511.
3. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557–1565.
4. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115–126.
5. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836–843.
6. Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation. 2001; 104: 63–67.
7. Van DM I, De Maat MP, Hak AE, et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam study. Stroke. 2002; 33: 2750–2755.
8. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111: 1805–1812.[CrossRef][Medline] [Order article via Infotrieve]
9. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology. 1999; 42: 23–30.[CrossRef][Medline] [Order article via Infotrieve]
10. Mold C, Gresham HD, Du Clos TW. Serum amyloid P component and C-reactive protein mediate phagocytosis through murine Fc gamma Rs. J Immunol. 2001; 166: 1200–1205.
11. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998; 18: 1386–1392.
12. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002; 106: 913–919.
13. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002; 106: 1439–1441.
14. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002; 105: 1890–1896.
15. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 2165–2168.
16. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001; 103: 2531–2534.
17. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000; 20: 2094–2099.
18. Chang MK, Binder CJ, Torzewski M, et al. From the Cover: C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A. 2002;99:13043–13048.
19. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001; 103: 1194–1197.
20. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003; 107: 1783–1790.
21. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res. 2003; 58: 186–195.
22. Sternik L, Samee S, Schaff HV, et al. C-reactive protein relaxes human vessels in vitro. Arterioscler Thromb Vasc Biol. 2002; 22: 1865–1868.
23. Moulton KS, Heller E, Konerding MA, et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999; 99: 1726–1732.
24. Moulton KS, Vakili K, Zurakowski D, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A. 2003;100:4736–4741.
25. Zhang SH, Reddick RL, Piedrahita JA, et al. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992; 258: 468–471.
26. Ciliberto G, Arcone R, Wagner EF, et al. Inducible and tissue-specific expression of human C-reactive protein in transgenic mice. EMBO J. 1987; 6: 4017–4022.[Medline] [Order article via Infotrieve]
27. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apoE. Arterioscler Thromb. 1994; 14: 141–147.
28. Todd NJ, Whicher JT, Westacott C, et al. The acute phase protein response in mice does not show tolerance to recurrent sterile inflammation. Clin Chim Acta. 1990; 189: 47–54.[CrossRef][Medline] [Order article via Infotrieve]
29. Chang BH-J, Liao W, Li L, et al. Liver-specific inactivation of the abetalipoproteinemia gene completely abrogates very low density lipoprotein/low density lipoprotein production in a viable conditional knockout mouse. J Biol Chem. 1999; 274: 6051–6055.
30. Krege JH, Hodgin JB, Hagaman JR, et al. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995; 25: 1111–1115.
31. Paul A, Calleja L, Vilella E, et al. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice with phenylhydrazine-induced anemia. Atherosclerosis. 1999; 147: 61–68.[CrossRef][Medline] [Order article via Infotrieve]
32. Calleja L, Paris MA, Paul A, et al. Low-cholesterol and high-fat diets reduce atherosclerotic lesion development in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 1999; 19: 2368–2375.
33. Guevara NV, Kim H-S, Antonova EI, et al. Absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med. 1999; 5: 335–339.[CrossRef][Medline] [Order article via Infotrieve]
34. Castro-Chavez F, Yechoor V, Saha PK, et al. Coordinated up-regulation of oxidative pathways and down-regulation of lipid biosynthesis underlie obesity resistance in perilipin knockout mice: a microarray gene expression profile. Diabetes. 2003; 52: 2666–2674.
35. Szalai AJ, Briles DE, Volanakis JE. Human C -reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol. 1995; 155: 2557–2563.[Abstract]
36. Yasojima K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001; 158: 1039–1051.
37. Yasojima K, Schwab C, McGeer EG, et al. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001; 21: 1214–1219.
38. Hansson GK, Holm J, Kral JG. Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions. Acta Pathol Microbiol Immunol Scand [A]. 1984; 92: 429–435.[Medline] [Order article via Infotrieve]
39. Buono C, Come CE, Witztum JL, et al. Influence of C3 deficiency on atherosclerosis. Circulation. 2002; 105: 3025–3031.
40. Kranzhofer R, Schmidt J, Pfeiffer CAH, et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999; 19: 1623–1629.
41. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000; 52: 11–34.
42. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000; 105: 1605–1612.[Medline] [Order article via Infotrieve]
43. Weiss D, Kools JJ, Taylor WR. Angiotensin II -induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation. 2001; 103: 448–454.
44. Scheidegger KJ, Butler S, Witztum JL. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem. 1997; 272: 21609–21615.
45. Sodhi CP, Kanwar YS, Sahai A. Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol. 2003; 284: H846–H852.
46. Su EJ, Lombardi DM, Wiener J, et al. Mitogenic effect of angiotensin II on rat carotid arteries and type II or III mesenteric microvessels but not type I mesenteric microvessels is mediated by endogenous basic fibroblast growth factor. Circ Res. 1998; 82: 321–327.
47. Ohta K, Kim S, Hamaguchi A, et al. Role of angiotensin II in extracellular matrix and transforming growth factor-beta 1 expression in hypertensive rats. Eur J Pharmacol. 1994; 269: 115–119.[CrossRef][Medline] [Order article via Infotrieve]
48. Dol F, Martin G, Staels B, et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E- deficient mice. J Cardiovasc Pharmacol. 2001; 38: 395–405.[CrossRef][Medline] [Order article via Infotrieve]
49. Tummala PE, Chen XL, Sundell CL, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation. 1999; 100: 1223–1229.
50. Pueyo ME, Gonzalez W, Nicoletti A, et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-b activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol. 2000; 20: 645–651.
51. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 2003; 108: 512–515.
This article has been cited by other articles:
 |
|
 |
|
  T. Koike, S. Kitajima, Y. Yu, K. Nishijima, J. Zhang, Y. Ozaki, M. Morimoto, T. Watanabe, S. Bhakdi, Y. Asada, et al. Human C-Reactive Protein Does Not Promote Atherosclerosis in Transgenic Rabbits Circulation, November 24, 2009; 120(21): 2088 - 2094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Danesh and M. B. Pepys C-Reactive Protein and Coronary Disease: Is There a Causal Link? Circulation, November 24, 2009; 120(21): 2036 - 2039. [Full Text] [PDF]
|
|
|
|
|
|
G. D. Norata, P. Marchesi, V. K. Pulakazhi Venu, F. Pasqualini, A. Anselmo, F. Moalli, I. Pizzitola, C. Garlanda, A. Mantovani, and A. L. Catapano Deficiency of the Long Pentraxin PTX3 Promotes Vascular Inflammation and Atherosclerosis Circulation, August 25, 2009; 120(8): 699 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Filep Platelets Affect the Structure and Function of C-Reactive Protein Circ. Res., July 17, 2009; 105(2): 109 - 111. [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Pons-Estel, L. A. Gonzalez, J. Zhang, P. I. Burgos, J. D. Reveille, L. M. Vila, and G. S. Alarcon Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort Rheumatology, July 1, 2009; 48(7): 817 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Ortiz, G. L. Campana, J. R. Woods, G. Boguslawski, M. J. Sosa, C. L. Walker, and C. A. Labarrere Continuously-Infused Human C-Reactive Protein Is Neither Proatherosclerotic Nor Proinflammatory in Apolipoprotein E-Deficient Mice Experimental Biology and Medicine, June 1, 2009; 234(6): 624 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wu, R. M. Gower, H. Wang, X.-Y. D. Perrard, R. Ma, D. C. Bullard, A. R. Burns, A. Paul, C. W. Smith, S. I. Simon, et al. Functional Role of CD11c+ Monocytes in Atherogenesis Associated With Hypercholesterolemia Circulation, May 26, 2009; 119(20): 2708 - 2717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Shih, S. Zhang, W. Cao, A. Hahn, J. Wang, J. E. Paulsen, and D. C. Harnish CRP is a novel ligand for the oxidized LDL receptor LOX-1 Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1643 - H1650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Xing, S. Nozell, Y.-F. Chen, F. Hage, and S. Oparil Estrogen and Mechanisms of Vascular Protection Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 289 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Guan, P. Wang, R. Hui, M. L. Edin, D. C. Zeldin, and D. W. Wang Adeno-Associated Virus-Mediated Human C-Reactive Protein Gene Delivery Causes Endothelial Dysfunction and Hypertension in Rats Clin. Chem., February 1, 2009; 55(2): 274 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shen and J. M. Ordovas Impact of Genetic and Environmental Factors on hsCRP Concentrations and Response to Therapeutic Agents Clin. Chem., February 1, 2009; 55(2): 256 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Devaraj, U. Singh, and I. Jialal The Evolving Role of C-Reactive Protein in Atherothrombosis Clin. Chem., February 1, 2009; 55(2): 229 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Howren, D. M. Lamkin, and J. Suls Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis Psychosom Med, February 1, 2009; 71(2): 171 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Molins, E. Pena, G. Vilahur, C. Mendieta, M. Slevin, and L. Badimon C-Reactive Protein Isoforms Differ in Their Effects on Thrombus Growth Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2239 - 2246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Montecucco, S. Steffens, F. Burger, G. Pelli, C. Monaco, and F. Mach C-reactive protein (CRP) induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes J. Leukoc. Biol., October 1, 2008; 84(4): 1109 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Young, I. Kushner, and D. Samols Binding of C/EBP{beta} to the C-Reactive Protein (CRP) Promoter in Hep3B Cells Is Associated with Transcription of CRP mRNA J. Immunol., August 15, 2008; 181(4): 2420 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Paul, B. H.-J. Chang, L. Li, V. K. Yechoor, and L. Chan Deficiency of Adipose Differentiation-Related Protein Impairs Foam Cell Formation and Protects Against Atherosclerosis Circ. Res., June 20, 2008; 102(12): 1492 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Loppnow, K. Werdan, and M. Buerke Invited review: Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms Innate Immunity, April 1, 2008; 14(2): 63 - 87. [Abstract] [PDF]
|
|
|
|
|
|
J. Wu, M. J. Stevenson, J. M. Brown, E. A. Grunz, T. L. Strawn, and W. P. Fay C-Reactive Protein Enhances Tissue Factor Expression by Vascular Smooth Muscle Cells: Mechanisms and In Vivo Significance Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 698 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Singh, M. V. Suresh, D. C. Prayther, J. P. Moorman, A. E. Rusinol, and A. Agrawal C-Reactive Protein-Bound Enzymatically Modified Low-Density Lipoprotein Does Not Transform Macrophages into Foam Cells J. Immunol., March 15, 2008; 180(6): 4316 - 4322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nishikawa, K. Hagihara, S. Serada, T. Isobe, A. Matsumura, J. Song, T. Tanaka, I. Kawase, T. Naka, and K. Yoshizaki Transcriptional Complex Formation of c-Fos, STAT3, and Hepatocyte NF-1{alpha} Is Essential for Cytokine-Driven C-Reactive Protein Gene Expression J. Immunol., March 1, 2008; 180(5): 3492 - 3501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dandona Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein Mayo Clin. Proc., March 1, 2008; 83(3): 333 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Xing, F. G. Hage, Y.-F. Chen, M. A. McCrory, W. Feng, G. A. Skibinski, E. Majid-Hassan, S. Oparil, and A. J. Szalai Exaggerated Neointima Formation in Human C-Reactive Protein Transgenic Mice Is IgG Fc Receptor Type I (Fc{gamma}RI)-Dependent Am. J. Pathol., January 1, 2008; 172(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Patel, C. A. King, S. R. Bailey, J. W. Holt, K. Venkatachalam, A. Agrawal, A. J. Valente, and B. Chandrasekar Interleukin-17 Stimulates C-reactive Protein Expression in Hepatocytes and Smooth Muscle Cells via p38 MAPK and ERK1/2-dependent NF-{kappa}B and C/EBPbeta Activation J. Biol. Chem., September 14, 2007; 282(37): 27229 - 27238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kovacs, P. Tornvall, R. Nilsson, J. Tegner, A. Hamsten, and J. Bjorkegren Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia PNAS, August 21, 2007; 104(34): 13768 - 13773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G O'Neill, D. A Isenberg, and A. Rahman Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus? Ann Rheum Dis, August 1, 2007; 66(8): 989 - 991. [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Thambidorai, S. J. Jaffer, T. K. Shah, W. J. Stewart, A. L. Klein, and M. S. Lauer Association of atheroma as assessed by intraoperative transoesophageal echocardiography with long-term mortality in patients undergoing cardiac surgery Eur. Heart J., June 6, 2007; (2007) ehm180v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Szmitko and S. Verma C-Reactive Protein and Reendothelialization: NO Involvement Circ. Res., May 25, 2007; 100(10): 1405 - 1407. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Chang, G. K. Sukhova, P. Libby, E. Schvartz, A. H. Lichtenstein, S. J. Field, C. Kennedy, S. Madhavarapu, J. Luo, D. Wu, et al. Deletion of the phosphoinositide 3-kinase p110{gamma} gene attenuates murine atherosclerosis PNAS, May 8, 2007; 104(19): 8077 - 8082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Yanbaeva, M. A. Dentener, E. C. Creutzberg, G. Wesseling, and E. F. M. Wouters Systemic Effects of Smoking Chest, May 1, 2007; 131(5): 1557 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Bisoendial, J. J. P. Kastelein, S. L. M. Peters, J. H. M. Levels, R. Birjmohun, J. I. Rotmans, D. Hartman, J. C. M. Meijers, M. Levi, and E. S. G. Stroes Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects J. Lipid Res., April 1, 2007; 48(4): 952 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Vongpatanasin, G. D. Thomas, R. Schwartz, L. A. Cassis, S. Osborne-Lawrence, L. Hahner, L. L. Gibson, S. Black, D. Samols, and P. W. Shaul C-Reactive Protein Causes Downregulation of Vascular Angiotensin Subtype 2 Receptors and Systolic Hypertension in Mice Circulation, February 27, 2007; 115(8): 1020 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Stenvinkel C-reactive protein--does it promote vascular disease? Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2718 - 2720. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhong, S.-H. Li, S.-M. Liu, P. E. Szmitko, X.-Q. He, P. W.M. Fedak, and S. Verma C-Reactive Protein Upregulates Receptor for Advanced Glycation End Products Expression in Human Endothelial Cells Hypertension, September 1, 2006; 48(3): 504 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Paffen and M. P.M. deMaat C-reactive protein in atherosclerosis: A causal factor? Cardiovasc Res, July 1, 2006; 71(1): 30 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cheng, D. Tempel, R. van Haperen, A. van der Baan, F. Grosveld, M. J.A.P. Daemen, R. Krams, and R. de Crom Atherosclerotic Lesion Size and Vulnerability Are Determined by Patterns of Fluid Shear Stress Circulation, June 13, 2006; 113(23): 2744 - 2753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Scirica, D. A. Morrow, S. Verma, S. Devaraj, I. Jialal, B. M. Scirica, D. A. Morrow, S. Verma, S. Devaraj, and I. Jialal The Verdict Is Still Out Circulation, May 2, 2006; 113(17): 2128 - 2151. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Skowasch, S Schrempf, C J Preusse, J A Likungu, A Welz, B Luderitz, and G Bauriedel Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins Heart, April 1, 2006; 92(4): 495 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bisoendial, R. Birjmohun, T. Keller, S. van Leuven, H. Levels, M. Levi, J. Kastelein, and E. Stroes Circ. Res., December 9, 2005; 97(12): e115 - e116. [Full Text] [PDF]
|
|
|
|
|
|
K. W. S. Ko, A. Paul, K. Ma, L. Li, and L. Chan Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE-/- and LDLR-/- mice J. Lipid Res., December 1, 2005; 46(12): 2586 - 2594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Mineo, A. K. Gormley, I. S. Yuhanna, S. Osborne-Lawrence, L. L. Gibson, L. Hahner, R. V. Shohet, S. Black, J. E. Salmon, D. Samols, et al. Fc{gamma}RIIB Mediates C-Reactive Protein Inhibition of Endothelial NO Synthase Circ. Res., November 25, 2005; 97(11): 1124 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M Carter Inflammation, thrombosis and acute coronary syndromes Diabetes and Vascular Disease Research, October 1, 2005; 2(3): 113 - 121. [Abstract] [PDF]
|
|
|
|
|
|
J. Torzewski C-Reactive Protein and Atherogenesis: New Insights from Established Animal Models Am. J. Pathol., October 1, 2005; 167(4): 923 - 925. [Full Text] [PDF]
|
|
|
|
|
|
H. Sun, T. Koike, T. Ichikawa, K. Hatakeyama, M. Shiomi, B. Zhang, S. Kitajima, M. Morimoto, T. Watanabe, Y. Asada, et al. C-Reactive Protein in Atherosclerotic Lesions: Its Origin and Pathophysiological Significance Am. J. Pathol., October 1, 2005; 167(4): 1139 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wang, S. Oparil, Y.-F. Chen, M. A. McCrory, G. A. Skibinski, W. Feng, and A. J. Szalai Estrogen Treatment Abrogates Neointima Formation in Human C-Reactive Protein Transgenic Mice Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2094 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T.H. Yeh A New Perspective on the Biology of C-Reactive Protein Circ. Res., September 30, 2005; 97(7): 609 - 611. [Full Text] [PDF]
|
|
|
|
|
|
E. Shagdarsuren, M. Wellner, J.-H. Braesen, J.-K. Park, A. Fiebeler, N. Henke, R. Dechend, P. Gratze, F. C. Luft, and D. N. Muller Complement Activation in Angiotensin II-Induced Organ Damage Circ. Res., September 30, 2005; 97(7): 716 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Inflammation, Atherosclerosis, and Aspects of Insulin Action Diabetes Care, September 1, 2005; 28(9): 2312 - 2319. [Full Text] [PDF]
|
|
|
|
|
|
J J C S Veldhuijzen van Zanten, C Ring, D Carroll, and G D Kitas Increased C reactive protein in response to acute stress in patients with rheumatoid arthritis Ann Rheum Dis, September 1, 2005; 64(9): 1299 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Schwedler, K. Amann, K. Wernicke, A. Krebs, M. Nauck, C. Wanner, L. A. Potempa, and J. Galle Native C-Reactive Protein Increases Whereas Modified C-Reactive Protein Reduces Atherosclerosis in Apolipoprotein E-Knockout Mice Circulation, August 16, 2005; 112(7): 1016 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nilsson CRP--Marker or Maker of Cardiovascular Disease? Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1527 - 1528. [Full Text] [PDF]
|
|
|
|
|
|
K. Reifenberg, H.-A. Lehr, D. Baskal, E. Wiese, S. C. Schaefer, S. Black, D. Samols, M. Torzewski, K. J. Lackner, M. Husmann, et al. Role of C-Reactive Protein in Atherogenesis: Can the Apolipoprotein E Knockout Mouse Provide the Answer? Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1641 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Trion, M.P.M. de Maat, J.W. Jukema, A. van der Laarse, M.C. Maas, E.H. Offerman, L.M. Havekes, A.J. Szalai, H.M.G. Princen, and J.J. Emeis No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1635 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Liu, S. Wang, A. Deb, K. A. Nath, Z. S. Katusic, J. P. McConnell, and N. M. Caplice Proapoptotic, Antimigratory, Antiproliferative, and Antiangiogenic Effects of Commercial C-Reactive Protein on Various Human Endothelial Cell Types In Vitro: Implications of Contaminating Presence of Sodium Azide in Commercial Preparation Circ. Res., July 22, 2005; 97(2): 135 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Second World Congress on the Insulin Resistance Syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy Diabetes Care, July 1, 2005; 28(7): 1821 - 1830. [Full Text] [PDF]
|
|
|
|
|
|
C. D. Buckley, G. E. Rainger, G. B. Nash, and K. Raza Endothelial cells, fibroblasts and vasculitis Rheumatology, July 1, 2005; 44(7): 860 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Szalai, G. S. Alarcon, J. Calvo-Alen, S. M. A. Toloza, M. A. McCrory, J. C. Edberg, G. McGwin Jr, H. M. Bastian, B. J. Fessler, L. M. Vila, et al. Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events Rheumatology, July 1, 2005; 44(7): 864 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Hirschfield, J. R. Gallimore, M. C. Kahan, W. L. Hutchinson, C. A. Sabin, G. M. Benson, A. P. Dhillon, G. A. Tennent, and M. B. Pepys Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice PNAS, June 7, 2005; 102(23): 8309 - 8314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Pepys CRP or not CRP? That Is the Question Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1091 - 1094. [Full Text] [PDF]
|
|
|
|
|
|
C. Arnaud, F. Burger, S. Steffens, N. R. Veillard, T. H. Nguyen, D. Trono, and F. Mach Statins Reduce Interleukin-6-Induced C-Reactive Protein in Human Hepatocytes: New Evidence for Direct Antiinflammatory Effects of Statins Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1231 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Zieske, R. P. Tracy, C. A. McMahan, E. E. Herderick, S. Homma, G. T. Malcom, H. C. McGill Jr, J. P. Strong, and for the Pathobiological Determinants of Atheroscle Elevated Serum C-Reactive Protein Levels and Advanced Atherosclerosis in Youth Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1237 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Taylor, J. C. Giddings, and C. W. van den Berg C-Reactive Protein-Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and Lipopolysaccharide Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1225 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Di Napoli, M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H. C.A. Emsley, S. Forconi, S. J. Hopkins, L. Masotti, et al. Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members Stroke, June 1, 2005; 36(6): 1316 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Berg and P. E. Scherer Adipose Tissue, Inflammation, and Cardiovascular Disease Circ. Res., May 13, 2005; 96(9): 939 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Bisoendial, J. J.P. Kastelein, J. H.M. Levels, J. J. Zwaginga, B. van den Bogaard, P. H. Reitsma, J. C.M. Meijers, D. Hartman, M. Levi, and E. S.G. Stroes Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans Circ. Res., April 15, 2005; 96(7): 714 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J. Lipid Res., March 1, 2005; 46(3): 389 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Kullo and C. M. Ballantyne Conditional Risk Factors for Atherosclerosis Mayo Clin. Proc., February 1, 2005; 80(2): 219 - 230. [Abstract] [PDF]
|
|
|
|
|
|
Y. Ivashchenko, F. Kramer, S. Schafer, A. Bucher, K. Veit, V. Hombach, A. Busch, O. Ritzeler, J. Dedio, and J. Torzewski Protein Kinase C Pathway Is Involved in Transcriptional Regulation of C-Reactive Protein Synthesis in Human Hepatocytes Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 186 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Manolov, C. Rocker, V. Hombach, G. U. Nienhaus, and J. Torzewski Ultrasensitive Confocal Fluorescence Microscopy of C-Reactive Protein Interacting With Fc{gamma}RIIa Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2372 - 2377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Black, I. Kushner, and D. Samols C-reactive Protein J. Biol. Chem., November 19, 2004; 279(47): 48487 - 48490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Recinos III, B. K. Carr, D. B. Bartos, I. Boldogh, J. R. Carmical, L. M. Belalcazar, and A. R. Brasier Liver gene expression associated with diet and lesion development in atherosclerosis-prone mice: induction of components of alternative complement pathway Physiol Genomics, September 16, 2004; 19(1): 131 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Blaschke, D. Bruemmer, F. Yin, Y. Takata, W. Wang, M. C. Fishbein, T. Okura, J. Higaki, K. Graf, E. Fleck, et al. C-Reactive Protein Induces Apoptosis in Human Coronary Vascular Smooth Muscle Cells Circulation, August 3, 2004; 110(5): 579 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF]
|
|
|
|
|
|
K. S. Meir and E. Leitersdorf Atherosclerosis in the Apolipoprotein E-Deficient Mouse: A Decade of Progress Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1006 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Angles-Cano How statins and fibrates lower CRP Blood, June 1, 2004; 103(11): 3996 - 3997. [Full Text] [PDF]
|
|
|
|
|
|
R. Kleemann, L. Verschuren, B.-J. de Rooij, J. Lindeman, M. M. de Maat, A. J. Szalai, H. M. G. Princen, and T. Kooistra Evidence for anti-inflammatory activity of statins and PPAR{alpha} activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro Blood, June 1, 2004; 103(11): 4188 - 4194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Verma, P. E. Szmitko, and E. T.H. Yeh C-Reactive Protein: Structure Affects Function Circulation, April 27, 2004; 109(16): 1914 - 1917. [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Tall C-Reactive Protein Reassessed N. Engl. J. Med., April 1, 2004; 350(14): 1450 - 1452. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||